Additionally, GLP-1 RAs with established CV benefitsspecifically liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatideare recommended for patients with T2DM and ASCVD to reduce CV events, regardless of baseline or target HbA1c levels or concurrent glucose-lowering therapy (Class I, LoE A)
For those seeking more modest amounts of weight loss, any of the currently available medications are likely to work and the choice can be driven by a variety of factors: insurance coverage, availability, formulation (injection vs oral), and ease of access and use
Adding 2.5 mL creates 4 mg per mL
Please review our quick handling checklist below: How do you ship orders to preserve compound stability
Can GLP-1 medications help with insulin resistance
Victoza is specifically indicated for use in treating type 2 diabetes